๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT ยท Real-Time Price ยท USD
0.2701
+0.0572 (26.87%)
Nov 20, 2026, 10:11 AM EST - Market open

Lakewood-Amedex Biotherapeutics Earnings Call Transcripts

Fiscal Year 2026

  • Nu-3 is a locally delivered gel candidate for infected diabetic foot ulcers, supported by rapid-kill and animal-model data. The Phase IIa study is ongoing, with topline results targeted for Q1 next year; positive results could lead to Phase IIb.

  • A novel class of antimicrobials, Bisphosphocins, is advancing in clinical development for diabetic foot ulcer infections, showing rapid bacterial kill, low resistance risk, and strong preclinical and early clinical results. A phase IIA trial is set for 2024, with broader pipeline and IP strength supporting future growth.